Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
Status:
Enrolling by invitation
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of tocilizumab in the treatment of generalized myasthenia
gravis (gMG) as an extension study for the participants who previously completed Study
tMG(NCT05067348).